Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alaunos Therapeutics Q3 2026 Results: Net Loss of $772K, Loss Narrows

Alaunos Therapeutics reported a net loss of $2.7 million for the nine months ended September 30, 2026, as it transitioned from TCR therapies to pulmonary arterial hypertension treatments. The company's cash position decreased to $615,000, and it recently acquired Velaris Therapeutics in October 2026 to bolster its pipeline.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-0.8-1.2
EPS (diluted, $ a share)$-0.31$-0.55

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TCRT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alaunos Therapeutics, Inc.: key numbers

Share price
$1.60Close, Nov 16
Market cap
$6.73M
Shares outstanding
4.21MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alaunos Therapeutics, Inc.

All →
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 following a private placement financing. As a result, the previously scheduled delisting hearing has been cancelled and the company's common stock will continue to trade on The Nasdaq Capital Market.

Counterparty
Nasdaq
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, due to continued non-compliance with the $2.5 million minimum stockholders' equity requirement. The company has requested a hearing before the Nasdaq Hearings Panel, currently scheduled for November 10, 2026, which has stayed any delisting action pending the outcome.

Counterparty
The Nasdaq Stock Market LLC
9:29 AM ET 8-K
M&A Deal

Alaunos Therapeutics M&A Deal with Velaris Therapeutics, Inc.

Alaunos Therapeutics completed the acquisition of Velaris Therapeutics through a two-step merger process, making Velaris a wholly owned subsidiary. As consideration, Alaunos issued 105,286 shares of Series B Preferred Stock and 33,054 shares of Series C Preferred Stock to Velaris stockholders, which are convertible into common stock subject to shareholder approval. Following the deal, Alaunos plans to change its name to Velaris Therapeutics, Inc. and effect a reverse stock split.

Counterparty
Velaris Therapeutics, Inc.
4:30 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting and is currently evaluating strategic alternatives to regain compliance.

Counterparty
The Nasdaq Stock Market LLC
4:31 PM ET 8-K
Capital Raise

Alaunos Therapeutics Capital Raise of $1.12M

Alaunos Therapeutics entered into a securities purchase agreement for a registered direct offering of 380,469 shares of common stock and 386,654 pre-funded warrants. The offering was priced at $1.46 per share, generating aggregate gross proceeds of approximately $1.12 million. The company intends to use the net proceeds for general corporate purposes and working capital.

Value
$1.12M
Counterparty
institutional investors

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.